Pesquisa
Educação
Soluções
Entrar
PT
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
TR - Turkish
JA - Japanese
Center of Experimental Therapeutics,
Department of Oncology,
Center of Experimental Therapeutics, Department of Oncology
Anne-Christine Thierry has not added Biography.
If you are Anne-Christine Thierry and would like to personalize this page please email our Author Liaison for assistance.
Intragastric and Intranasal Administration of Lactobacillus paracasei NCC2461 Modulates Allergic Airway Inflammation in Mice.
International journal of inflammation , 2012 | Pubmed ID: 22762009
Novel birch pollen specific immunotherapy formulation based on contiguous overlapping peptides.
Clinical and translational allergy Jun, 2013 | Pubmed ID: 23725004
Safety and immunogenicity of immunotherapy with Bet v 1-derived contiguous overlapping peptides.
The Journal of allergy and clinical immunology Jul, 2014 | Pubmed ID: 24797422
Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial.
AIDS (London, England) Jul, 2014 | Pubmed ID: 24911353
Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial.
The Lancet. Respiratory medicine Dec, 2015 | Pubmed ID: 26598141
The Candidate Blood-stage Malaria Vaccine P27A Induces a Robust Humoral Response in a Fast Track to the Field Phase 1 Trial in Exposed and Nonexposed Volunteers.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 01, 2019 | Pubmed ID: 29945169
50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.
International journal of radiation oncology, biology, physics 02, 2019 | Pubmed ID: 30267761
A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three Patients.
Frontiers in immunology , 2019 | Pubmed ID: 31440238
Centre Hospitalier Universitaire Vaudois
Mukul Girotra*,1,2,
Anne-Christine Thierry3,
Alexandre Harari1,3,
George Coukos1,
Olaia Naveiras2,4,
Nicola Vannini*,1
1Department of Oncology UNIL CHUV, Ludwig Institute for Cancer Research Lausanne, University of Lausanne,
2Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology Lausanne (EPFL),
3Center of Experimental Therapeutics, Department of Oncology, Centre Hospitalier Universitaire Vaudois,
4Hematology Service, Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV)
Privacidade
Termos de uso
Políticas
Entre em contato
recomende à biblioteca
Newsletter
JoVE Journal
Coleções de métodos
JoVE Encyclopedia of Experiments
Arquivo
JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
Centro de Recursos para Docentes
Autores
Bibliotecários
Acesso
SOBRE A JoVE
Copyright © 2024 MyJoVE Corporation. Todos os direitos reservados